Holen Sie sich die Stockscreener-App
9.1213
0.66%
0.0413
Schlusskurs vom Vortag:
$9.08
Offen:
$9.12
24-Stunden-Volumen:
115.82K
Relative Volume:
0.11
Marktkapitalisierung:
$1.00B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-227.05M
KGV:
-4.146
EPS:
-2.2
Netto-Cashflow:
$-177.93M
1W Leistung:
-5.28%
1M Leistung:
-22.93%
6M Leistung:
+15.40%
1J Leistung:
+32.85%
1-Tages-Spanne:
$9.07
$9.27
1-Wochen-Bereich:
$8.56
$9.67
52-Wochen-Spanne:
$3.67
$12.61
Cogent Biosciences Inc Stock (COGT) Company Profile
Firmenname
Cogent Biosciences Inc
Sektor
Branche
Telefon
617-945-5576
Adresse
275 WYMAN STREET, WALTHAM
Vergleichen Sie COGT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| COGT | 9.15 | 1.00B | 0 | -227.05M | -177.93M | -2.20 |
| VRTX | 446.78 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.98 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.94 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Eingeleitet | Citigroup | Buy |
| 2023-12-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-12-08 | Eingeleitet | JP Morgan | Overweight |
| 2023-04-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-03-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-06-28 | Eingeleitet | Guggenheim | Buy |
| 2021-10-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-06-09 | Fortgesetzt | Jefferies | Buy |
| 2020-12-23 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Cogent Biosciences Inc Aktie (COGT) Neueste Nachrichten
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $21.00 at JPMorgan Chase & Co. - Defense World
FY2024 EPS Forecast for Cogent Biosciences Lifted by Analyst - MarketBeat
Trend Tracker for (COGT) - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Shares Down 7%Should You Sell? - MarketBeat
Lifesci Capital Has Negative Outlook of COGT FY2024 Earnings - Defense World
Equities Analysts Offer Predictions for COGT FY2024 Earnings - Defense World
Leerink Partnrs Has Strong Forecast for COGT FY2027 Earnings - MarketBeat
Wedbush Research Analysts Lower Earnings Estimates for COGT - MarketBeat
FY2024 Earnings Estimate for COGT Issued By Lifesci Capital - MarketBeat
COMMODORE CAPITAL LP's Strategic Acquisition in Cogent Biosciences Inc - GuruFocus.com
Wedbush Reaffirms “Neutral” Rating for Cogent Biosciences (NASDAQ:COGT) - Defense World
Cogent Biosciences (NASDAQ:COGT) Announces Earnings Results, Misses Expectations By $0.07 EPS - MarketBeat
Needham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00 - MarketBeat
Cogent Biosciences Inc (COGT) Quarterly 10-Q Report - Quartz
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing - TipRanks
Cogent Biosciences Inc Reports Q3 2024 Net Loss Per Share of $0. - GuruFocus.com
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results - GlobeNewswire
Cogent Biosciences Reports Strong Pipeline Progress, $346M Cash Position Despite Q3 Losses | COGT Stock News - StockTitan
Creative Planning Buys 3,272 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Cogent Biosciences’ (COGT) Buy Rating Reaffirmed at HC Wainwright - Defense World
FMR LLC Acquires Additional Shares in Cogent Biosciences Inc - GuruFocus.com
(COGT) Trading Advice - Stock Traders Daily
Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3%Here's What Happened - MarketBeat
Cogent Biosciences Announces Bezuclastinib Presentations at - GlobeNewswire
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting - The Manila Times
Cogent Biosciences to Present Key Bezuclastinib Trial Data at ASH 2024 Meeting | COGT Stock News - StockTitan
Cogent Biosciences' (COGT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives $14.67 Average PT from Brokerages - Defense World
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(COGT) Investment Analysis - Stock Traders Daily
Hennion & Walsh Asset Management Inc. Purchases 44,287 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Cogent Biosciences' (COGT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Cogent Biosciences expands pipeline with KRAS inhibitor - Investing.com
Cogent Biosciences expands pipeline with KRAS inhibitor By Investing.com - Investing.com UK
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics - StockTitan
Cogent Biosciences Announces Pipeline Expansion into KRAS - GlobeNewswire
COGT Stock Hits 52-Week High at $12.2 Amid Market Optimism - Investing.com India
Cogent Biosciences (NASDAQ:COGT) Sets New 52-Week HighHere's What Happened - MarketBeat
Here's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn Situation - Yahoo Finance
SG Americas Securities LLC Acquires New Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
The Manufacturers Life Insurance Company Has $301,000 Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT) - Defense World
Market Momentum Report: Cogent Biosciences Inc (COGT)’s Negative Close at 11.35 - The Dwinnex
Cogent Biosciences (NASDAQ:COGT) Shares Down 2.4%What's Next? - MarketBeat
(COGT) Technical Data - Stock Traders Daily
Stocks of Cogent Biosciences Inc (COGT) are poised to climb above their peers - SETE News
Cogent Biosciences (NASDAQ:COGT) Stock Price Up 4.6%Here's What Happened - MarketBeat
Did Cogent Biosciences Inc (COGT) perform well in the last session? - US Post News
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target - Insider Monkey
Get in on Cogent Biosciences Inc’s (COGT) buy-in window today! - SETE News
Metric Deep Dive: Understanding Cogent Biosciences Inc (COGT) Through its Ratios - The Dwinnex
Dimensional Fund Advisors LP Has $7.84 Million Stake in Cogent Biosciences, Inc. (NASDAQ:COGT) - MarketBeat
Finanzdaten der Cogent Biosciences Inc-Aktie (COGT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):